On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM).
In this presentation, Popat discusses the importance of health-related QoL as a key clinical outcome in MM, particularly in the context of increasingly effective therapies. Popat emphasizes the need to balance efficacy and safety with QoL and outlines patient-, disease-, and treatment-related factors that influence QoL. Practical considerations, including treatment logistics, adverse events, and patient preferences, are also discussed, alongside approaches to assessing QoL and incorporating shared decision-making into clinical practice.
This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity.
","author_name":"Scientific Education Support"}